| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Amyloid removal and the appearance of brain volume loss
|
Hyman, Bradley T
|
|
|
23 |
10 |
p. 957-958
|
artikel
|
| 2 |
Brain volume change following anti-amyloid β immunotherapy for Alzheimer's disease: amyloid-removal-related pseudo-atrophy
|
Belder, Christopher R S
|
|
|
23 |
10 |
p. 1025-1034
|
artikel
|
| 3 |
Christopher Ross: diseases of the brain, not the mind
|
Cavanaugh, Ray
|
|
|
23 |
10 |
p. 968
|
artikel
|
| 4 |
Considerations for future trials in cerebral cavernous malformations
|
Alawieh, Ali M
|
|
|
23 |
10 |
p. 964-965
|
artikel
|
| 5 |
Considerations for future trials in cerebral cavernous malformations
|
Cenzato, Marco
|
|
|
23 |
10 |
p. 965
|
artikel
|
| 6 |
Considerations for future trials in cerebral cavernous malformations – Authors' reply
|
|
|
|
23 |
10 |
p. 965-966
|
artikel
|
| 7 |
Diagnosis of multiple sclerosis: challenges and opportunities
|
Wallin, Mitchell
|
|
|
23 |
10 |
p. 958-960
|
artikel
|
| 8 |
Differential diagnosis of suspected multiple sclerosis: considerations in people from minority ethnic and racial backgrounds in North America, northern Europe, and Australasia
|
Amezcua, Lilyana
|
|
|
23 |
10 |
p. 1050-1062
|
artikel
|
| 9 |
Differential diagnosis of suspected multiple sclerosis: global health considerations
|
Correale, Jorge
|
|
|
23 |
10 |
p. 1035-1049
|
artikel
|
| 10 |
Global burden of stroke: dynamic estimates to inform action
|
Wu, Simiao
|
|
|
23 |
10 |
p. 952-953
|
artikel
|
| 11 |
Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
|
|
|
|
23 |
10 |
p. 973-1003
|
artikel
|
| 12 |
Health as a philosophical idea
|
Madrid-Casado, Carlos M
|
|
|
23 |
10 |
p. 969
|
artikel
|
| 13 |
Important considerations for children with non-dystrophic myotonia
|
Henzi, Bettina C
|
|
|
23 |
10 |
p. 953-955
|
artikel
|
| 14 |
Improving access to medicines for neurological disorders
|
The Lancet Neurology,
|
|
|
23 |
10 |
p. 951
|
artikel
|
| 15 |
Mexiletine versus lamotrigine in non-dystrophic myotonias: a randomised, double-blind, head-to-head, crossover, non-inferiority, phase 3 trial
|
Vivekanandam, Vinojini
|
|
|
23 |
10 |
p. 1004-1012
|
artikel
|
| 16 |
Navigating the roads ahead for Alzheimer's disease
|
Stirrups, Robert
|
|
|
23 |
10 |
p. 971
|
artikel
|
| 17 |
Non-inferiority design for trials in multiple sclerosis
|
Sormani, Maria Pia
|
|
|
23 |
10 |
p. 970
|
artikel
|
| 18 |
On the trail of Edinburgh's neuroscience past and present
|
Ranscombe, Peter
|
|
|
23 |
10 |
p. 972
|
artikel
|
| 19 |
RAB32 mutation in Parkinson's disease
|
Monfrini, Edoardo
|
|
|
23 |
10 |
p. 961-962
|
artikel
|
| 20 |
RAB32 mutation in Parkinson's disease
|
Beetz, Christian
|
|
|
23 |
10 |
p. 961
|
artikel
|
| 21 |
RAB32 mutation in Parkinson's disease
|
Zhao, Yuwen
|
|
|
23 |
10 |
p. 962-963
|
artikel
|
| 22 |
RAB32 mutation in Parkinson's disease
|
Gómez-Garre, Pilar
|
|
|
23 |
10 |
p. 962
|
artikel
|
| 23 |
RAB32 mutation in Parkinson's disease – Author's reply
|
Farrer, Matthew J
|
|
|
23 |
10 |
p. 963-964
|
artikel
|
| 24 |
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial
|
Allen, Jeffrey A
|
|
|
23 |
10 |
p. 1013-1024
|
artikel
|
| 25 |
Shaida Khan
|
|
|
|
23 |
10 |
p. 969
|
artikel
|
| 26 |
Targeting auto-antibodies for CIDP: hope and questions
|
Rajabally, Yusuf A
|
|
|
23 |
10 |
p. 955-956
|
artikel
|
| 27 |
The Yaoundé Declaration
|
Njamnshi, Alfred K
|
|
|
23 |
10 |
p. 966-967
|
artikel
|
Tijdschrift beschrijving